{"id":"W2007200101","doi":"10.1016/j.clim.2014.06.006","title":"Targeting the IL-17/IFN-γ axis as a potential new clinical therapy for type 1 diabetes","year":2014,"lang":"en","type":"review","venue":"Clinical Immunology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":50,"is_retracted":false,"has_abstract":false,"ca_institutions":"Child and Family Research Institute; University of British Columbia","funders":"","keywords":"Ustekinumab; Medicine; Immunology; Type 1 diabetes; Psoriasis; Interleukin 23; Secretion; Monoclonal antibody; Disease; Type 2 diabetes; Blockade; Monoclonal; Diabetes mellitus; Interleukin 17; Antibody; Cytokine; Internal medicine; Endocrinology; Tumor necrosis factor alpha; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.003387734,0.0009787583,0.004764119,0.0001506357,0.0005317326,0.00005264785,0.001682001,0.004095431,0.001210202],"category_scores_gemma":[0.003353901,0.0005936155,0.003377182,0.0002959015,0.001305269,0.00006095627,0.0004116793,0.001892418,0.004965249],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004911209,"about_ca_system_score_gemma":0.0009532552,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003046808,"about_ca_topic_score_gemma":0.00000562735,"domain_scores_codex":[0.9895579,0.004456105,0.003331216,0.001403017,0.0000646037,0.001187187],"domain_scores_gemma":[0.9860511,0.01058522,0.001592642,0.001457109,0.0002175775,0.00009632386],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0005027058,0.0004008814,0.00009959299,0.0001727012,0.007144747,0.000005746686,0.00001909358,1.555883e-7,0.00002916594,0.0001769688,0.05741156,0.9340367],"study_design_scores_gemma":[0.003447765,0.003160671,0.0001533815,0.0005553747,0.003109588,0.00004489372,0.0000174919,0.000001082359,0.0000136952,0.0005166166,0.9883633,0.0006160983],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001232993,0.9782062,0.00008411719,0.0004379691,0.01742832,0.002065502,0.0001529263,0.0001782147,0.0002138093],"genre_scores_gemma":[0.0001140539,0.9828846,0.0002079973,0.0008642046,0.002492929,0.0003261392,0.001849429,0.000146572,0.01111404],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9334206,"threshold_uncertainty_score":0.9997028,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1146624484401171,"score_gpt":0.4090297676395804,"score_spread":0.2943673191994634,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}